首页 > 最新文献

Translational gastroenterology and hepatology最新文献

英文 中文
Post-cholecystectomy syndrome: a retrospective study analysing the associated demographics, aetiology, and healthcare utilization. 胆囊切除术后综合征:一项回顾性研究,分析了相关的人口统计学、病因学和医疗保健利用。
IF 3 4区 医学 Q1 Medicine Pub Date : 2021-10-25 eCollection Date: 2021-01-01 DOI: 10.21037/tgh.2019.11.08
Saad Saleem, Simcha Weissman, Hector Gonzalez, Patricia Guzman Rojas, Faisal Inayat, Ali Alshati, Vinaya Gaduputi

Background: Post-cholecystectomy syndrome (PCS) is a group of heterogeneous signs and symptoms, predominately consisting of right upper quadrant abdominal pain, dyspepsia, and/or jaundice, manifesting after undergoing a cholecystectomy. According to some studies, as many as 40% of post-cholecystectomy patients are in fact, affected by this syndrome. This study aims to determine the demographics, aetiology, average length of hospital stay, and health care burden associated with PCS.

Methods: We queried the National Inpatient Sample (NIS) database to determine inpatient admissions of PCS between 2011 and 2014 using the ICD-9 primary diagnosis code 576.0.

Results: From 2011 to 2014, the number of inpatient admissions with a principal diagnosis of PCS totally 275. The average length of hospital stay was 4.28±4.28, 3.42±2.73, 3.74±1.84, and 3.79±2.78 days in 2011, 2012, 2013, and 2014, respectively. The total yearly charges were $32,079±$24,697, $27,019±$22,633, $34,898.21±$24,408, and $35,204±$32,951 in 2011, 2012, 2013, and 2014, respectively. Notably, the primary cause of PCS in our patient sample between the year 2011 and 2014, was biliary duct dysfunction, followed by Peptic ulcer disease.

Conclusions: In conclusion, there is a strong need to examine for and treat the underlying aetiology when approaching a post-cholecystectomy patient. We found that longer hospital stays, were associated with a greater health care burden, and visa versa. Furthermore, our findings help identify at-risk populations which can contribute to improving surveillance of this costly disease.

背景:胆囊切除术后综合征(PCS)是一组异质性体征和症状,主要包括胆囊切除术后出现的右上腹部疼痛、消化不良和/或黄疸。根据一些研究,事实上,多达40%的胆囊切除术后患者受到这种综合征的影响。本研究旨在确定与PCS相关的人口统计学、病因学、平均住院时间和卫生保健负担。方法:使用ICD-9初诊代码576.0查询国家住院患者样本(NIS)数据库,确定2011 - 2014年住院PCS患者。结果:2011 - 2014年,以PCS为主要诊断的住院患者共275例。2011年、2012年、2013年、2014年的平均住院时间分别为4.28±4.28、3.42±2.73、3.74±1.84、3.79±2.78天。2011年、2012年、2013年和2014年的年总费用分别为32,079±24,697美元、27,019±22,633美元、34,898.21±24,408美元和35,204±32,951美元。值得注意的是,在我们的患者样本中,2011年至2014年发生PCS的主要原因是胆管功能障碍,其次是消化性溃疡疾病。结论:总之,在接近胆囊切除术后患者时,强烈需要检查和治疗潜在的病因。我们发现,住院时间越长,医疗负担越重,反之亦然。此外,我们的发现有助于确定高危人群,从而有助于改善对这种代价高昂的疾病的监测。
{"title":"Post-cholecystectomy syndrome: a retrospective study analysing the associated demographics, aetiology, and healthcare utilization.","authors":"Saad Saleem,&nbsp;Simcha Weissman,&nbsp;Hector Gonzalez,&nbsp;Patricia Guzman Rojas,&nbsp;Faisal Inayat,&nbsp;Ali Alshati,&nbsp;Vinaya Gaduputi","doi":"10.21037/tgh.2019.11.08","DOIUrl":"https://doi.org/10.21037/tgh.2019.11.08","url":null,"abstract":"<p><strong>Background: </strong>Post-cholecystectomy syndrome (PCS) is a group of heterogeneous signs and symptoms, predominately consisting of right upper quadrant abdominal pain, dyspepsia, and/or jaundice, manifesting after undergoing a cholecystectomy. According to some studies, as many as 40% of post-cholecystectomy patients are in fact, affected by this syndrome. This study aims to determine the demographics, aetiology, average length of hospital stay, and health care burden associated with PCS.</p><p><strong>Methods: </strong>We queried the National Inpatient Sample (NIS) database to determine inpatient admissions of PCS between 2011 and 2014 using the ICD-9 primary diagnosis code 576.0.</p><p><strong>Results: </strong>From 2011 to 2014, the number of inpatient admissions with a principal diagnosis of PCS totally 275. The average length of hospital stay was 4.28±4.28, 3.42±2.73, 3.74±1.84, and 3.79±2.78 days in 2011, 2012, 2013, and 2014, respectively. The total yearly charges were $32,079±$24,697, $27,019±$22,633, $34,898.21±$24,408, and $35,204±$32,951 in 2011, 2012, 2013, and 2014, respectively. Notably, the primary cause of PCS in our patient sample between the year 2011 and 2014, was biliary duct dysfunction, followed by Peptic ulcer disease.</p><p><strong>Conclusions: </strong>In conclusion, there is a strong need to examine for and treat the underlying aetiology when approaching a post-cholecystectomy patient. We found that longer hospital stays, were associated with a greater health care burden, and visa versa. Furthermore, our findings help identify at-risk populations which can contribute to improving surveillance of this costly disease.</p>","PeriodicalId":23267,"journal":{"name":"Translational gastroenterology and hepatology","volume":" ","pages":"58"},"PeriodicalIF":3.0,"publicationDate":"2021-10-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8573368/pdf/tgh-06-2019.11.08.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39644662","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 3
Value of alpha-fetoprotein in hepatocellular carcinoma. 甲胎蛋白在肝细胞癌中的价值。
IF 3 4区 医学 Q1 Medicine Pub Date : 2021-10-25 eCollection Date: 2021-01-01 DOI: 10.21037/tgh.2019.12.19
Wei-Chen Lee
{"title":"Value of alpha-fetoprotein in hepatocellular carcinoma.","authors":"Wei-Chen Lee","doi":"10.21037/tgh.2019.12.19","DOIUrl":"https://doi.org/10.21037/tgh.2019.12.19","url":null,"abstract":"","PeriodicalId":23267,"journal":{"name":"Translational gastroenterology and hepatology","volume":" ","pages":"52"},"PeriodicalIF":3.0,"publicationDate":"2021-10-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8573367/pdf/tgh-06-2019.12.19.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39756325","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 3
Endoscopic therapies for Barrett's esophagus. 巴雷特食管的内镜治疗。
IF 3 4区 医学 Q1 Medicine Pub Date : 2021-10-25 eCollection Date: 2021-01-01 DOI: 10.21037/tgh.2020.02.04
Scott Ventre, Haroon Shahid

The management of Barrett's esophagus (BE) has evolved as newer technologies and novel methods are developed. Endoscopic mucosal resection (EMR) or endoscopic submucosal dissection (ESD) are the initial interventions of choice for nodular BE, with ESD reserved for endoscopists highly trained in the technique and for larger lesions that would warrant en bloc resection. Resection should then be followed by ablative therapy, which remains first line in the treatment of BE with dysplasia. Although there is a myriad of ablation techniques available to the endoscopist, this review has found that radiofrequency ablation (RFA) continues to have the most robust safety and efficacy data to support its use despite a relatively high rate of recurrence. Cryotherapy and Hybrid-APC appear to be safe and effective as RFA alternatives, but further trials are still needed to directly compare their outcomes to RFA and ultimately guide changes in treatment decisions.

巴雷特食管(BE)的治疗随着新技术和新方法的发展而不断发展。内镜下粘膜切除(EMR)或内镜下粘膜剥离(ESD)是结节性BE的首选干预措施,ESD仅用于训练有素的内镜医师和需要整体切除的较大病变。切除后应进行消融治疗,这仍然是治疗伴有不典型增生的be的一线方法。虽然有无数的消融技术可供内窥镜医师使用,但本综述发现射频消融(RFA)尽管复发率相对较高,但仍然具有最可靠的安全性和有效性数据来支持其使用。冷冻疗法和Hybrid-APC似乎是安全有效的RFA替代方案,但仍需要进一步的试验来直接比较它们与RFA的结果,并最终指导治疗决策的变化。
{"title":"Endoscopic therapies for Barrett's esophagus.","authors":"Scott Ventre,&nbsp;Haroon Shahid","doi":"10.21037/tgh.2020.02.04","DOIUrl":"https://doi.org/10.21037/tgh.2020.02.04","url":null,"abstract":"<p><p>The management of Barrett's esophagus (BE) has evolved as newer technologies and novel methods are developed. Endoscopic mucosal resection (EMR) or endoscopic submucosal dissection (ESD) are the initial interventions of choice for nodular BE, with ESD reserved for endoscopists highly trained in the technique and for larger lesions that would warrant <i>en bloc</i> resection. Resection should then be followed by ablative therapy, which remains first line in the treatment of BE with dysplasia. Although there is a myriad of ablation techniques available to the endoscopist, this review has found that radiofrequency ablation (RFA) continues to have the most robust safety and efficacy data to support its use despite a relatively high rate of recurrence. Cryotherapy and Hybrid-APC appear to be safe and effective as RFA alternatives, but further trials are still needed to directly compare their outcomes to RFA and ultimately guide changes in treatment decisions.</p>","PeriodicalId":23267,"journal":{"name":"Translational gastroenterology and hepatology","volume":" ","pages":"62"},"PeriodicalIF":3.0,"publicationDate":"2021-10-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8573364/pdf/tgh-06-2020.02.04.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39644666","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Narrative review of current and emerging pharmacological therapies for nonalcoholic steatohepatitis. 非酒精性脂肪性肝炎目前和新出现的药物治疗的叙述性回顾。
IF 3 4区 医学 Q1 Medicine Pub Date : 2021-10-25 eCollection Date: 2021-01-01 DOI: 10.21037/tgh-20-247
Jinendra Satiya, Heather S Snyder, Shivaram Prasad Singh, Sanjaya K Satapathy

Nonalcoholic steatohepatitis (NASH) is the most common cause of chronic liver disease today, and it has now emerged as the leading etiology of end-stage liver disease requiring liver transplantation. It is a progressive form of non-alcoholic fatty liver disease which can not only progress to cirrhosis of liver and hepatocellular carcinoma (HCC), but is associated with increased cardiovascular risks too. Despite all the advances in the understanding of the risk factors and the pathogenetic pathways involved in the pathogenesis and progression of NASH, an effective therapy for NASH has not been developed yet. Although lifestyle modifications including dietary modifications and physical activity remain the mainstay of therapy, there is an unmet need to develop a drug or a combination of drugs which can not only reduce the fatty infiltration of the liver, but also arrest the development and progression of fibrosis and advancement to cirrhosis of liver and HCC. The pharmacologic therapies which are being developed target the various components believed to be involved in the pathogenesis of nonalcoholic fatty liver disease (NAFLD)/NASH which includes insulin resistance, lipid metabolism oxidative stress, lipid peroxidation, inflammatory and cell death pathways, and fibrosis. In this review, we summarize the current state of knowledge on pharmacotherapy of NASH, and also highlight the recent developments in the field, for optimizing the management and treatment of NASH.

非酒精性脂肪性肝炎(NASH)是当今慢性肝病最常见的病因,现已成为需要肝移植的终末期肝病的主要病因。它是一种非酒精性脂肪性肝病的进行性形式,不仅可以发展为肝硬化和肝细胞癌(HCC),而且还与心血管风险增加有关。尽管对NASH发病和进展的危险因素和发病途径的了解取得了进展,但尚未开发出有效的NASH治疗方法。虽然包括饮食调整和体育锻炼在内的生活方式改变仍然是治疗的主要方法,但目前还没有满足开发一种药物或药物联合治疗的需求,这种药物或药物联合治疗不仅可以减少肝脏的脂肪浸润,还可以阻止纤维化的发展和进展,并阻止肝硬化和HCC的发展。正在开发的药物治疗针对被认为与非酒精性脂肪性肝病(NAFLD)/NASH发病机制有关的各种成分,包括胰岛素抵抗、脂质代谢氧化应激、脂质过氧化、炎症和细胞死亡途径以及纤维化。在这篇综述中,我们总结了NASH药物治疗的现状,并重点介绍了该领域的最新进展,以优化NASH的管理和治疗。
{"title":"Narrative review of current and emerging pharmacological therapies for nonalcoholic steatohepatitis.","authors":"Jinendra Satiya,&nbsp;Heather S Snyder,&nbsp;Shivaram Prasad Singh,&nbsp;Sanjaya K Satapathy","doi":"10.21037/tgh-20-247","DOIUrl":"https://doi.org/10.21037/tgh-20-247","url":null,"abstract":"<p><p>Nonalcoholic steatohepatitis (NASH) is the most common cause of chronic liver disease today, and it has now emerged as the leading etiology of end-stage liver disease requiring liver transplantation. It is a progressive form of non-alcoholic fatty liver disease which can not only progress to cirrhosis of liver and hepatocellular carcinoma (HCC), but is associated with increased cardiovascular risks too. Despite all the advances in the understanding of the risk factors and the pathogenetic pathways involved in the pathogenesis and progression of NASH, an effective therapy for NASH has not been developed yet. Although lifestyle modifications including dietary modifications and physical activity remain the mainstay of therapy, there is an unmet need to develop a drug or a combination of drugs which can not only reduce the fatty infiltration of the liver, but also arrest the development and progression of fibrosis and advancement to cirrhosis of liver and HCC. The pharmacologic therapies which are being developed target the various components believed to be involved in the pathogenesis of nonalcoholic fatty liver disease (NAFLD)/NASH which includes insulin resistance, lipid metabolism oxidative stress, lipid peroxidation, inflammatory and cell death pathways, and fibrosis. In this review, we summarize the current state of knowledge on pharmacotherapy of NASH, and also highlight the recent developments in the field, for optimizing the management and treatment of NASH.</p>","PeriodicalId":23267,"journal":{"name":"Translational gastroenterology and hepatology","volume":" ","pages":"60"},"PeriodicalIF":3.0,"publicationDate":"2021-10-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8573363/pdf/tgh-06-20-247.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39644664","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 9
Ablative therapies of the biliary tree. 胆道的消融治疗。
IF 3 4区 医学 Q1 Medicine Pub Date : 2021-10-25 eCollection Date: 2021-01-01 DOI: 10.21037/tgh.2020.02.03
Elizabeth S John, Paul R Tarnasky, Prashant Kedia

Cholangiocarcinoma, a malignancy of the epithelial cells in the intrahepatic or extrahepatic biliary tree, is often diagnosed at later stages. Median survival duration ranges from 3 to 9 months with a less than ten percent 5-year survival rate. Thus, often treatment strategies are aimed more towards palliation instead of cure. With the majority of patients presenting with unresectable disease at the time of diagnosis, surgical intervention is not feasible, making less invasive endoscopic therapies more suitable. Initially, biliary stents were utilized for biliary decompression to mitigate cholestatic symptoms and prevent cholangitis; however, this strategy did not prove to provide significant survival benefit. Therefore, efforts to treat the tumor burden itself in addition to maintaining biliary patency became a focus of innovation and research in the endoscopic field. This study has led to the advent of therapies such as photodynamic therapy, radiofrequency ablation, and intraluminal brachytherapy. These options combined with biliary stenting have shown to not only offer the benefit of biliary decompression, but also to potentially improve stent patency and survival. Further, there is an anti-tumor effect of each of these modalities, portending an additional benefit in this subset of patients. Despite numerous retrospective and prospective studies assessing these ablative therapies, there is still a paucity of appropriately powered randomized controlled trials, and further research has yet to be done in the field. This review details the current literature entailing endobiliary ablative strategies.

胆管癌是肝内或肝外胆道上皮细胞的恶性肿瘤,通常在晚期才被诊断出来。中位生存期为3 - 9个月,5年生存率低于10%。因此,治疗策略往往更倾向于缓解而不是治愈。由于大多数患者在诊断时出现不可切除的疾病,手术干预是不可行的,因此更适合微创内镜治疗。最初,胆道支架用于胆道减压,以减轻胆汁淤积症状并预防胆管炎;然而,这种策略并没有被证明提供显著的生存效益。因此,在维持胆道通畅的同时,如何治疗肿瘤本身的负担成为内镜领域创新和研究的重点。这项研究导致了诸如光动力治疗、射频消融和腔内近距离治疗等治疗方法的出现。这些选择与胆道支架置入术相结合,不仅可以提供胆道减压的好处,而且还可以潜在地提高支架的通畅性和生存率。此外,每种方式都有抗肿瘤作用,预示着这部分患者的额外益处。尽管有大量的回顾性和前瞻性研究评估了这些消融疗法,但仍然缺乏适当的随机对照试验,该领域的进一步研究还有待完成。这篇综述详细介绍了目前有关内胆消融策略的文献。
{"title":"Ablative therapies of the biliary tree.","authors":"Elizabeth S John,&nbsp;Paul R Tarnasky,&nbsp;Prashant Kedia","doi":"10.21037/tgh.2020.02.03","DOIUrl":"https://doi.org/10.21037/tgh.2020.02.03","url":null,"abstract":"<p><p>Cholangiocarcinoma, a malignancy of the epithelial cells in the intrahepatic or extrahepatic biliary tree, is often diagnosed at later stages. Median survival duration ranges from 3 to 9 months with a less than ten percent 5-year survival rate. Thus, often treatment strategies are aimed more towards palliation instead of cure. With the majority of patients presenting with unresectable disease at the time of diagnosis, surgical intervention is not feasible, making less invasive endoscopic therapies more suitable. Initially, biliary stents were utilized for biliary decompression to mitigate cholestatic symptoms and prevent cholangitis; however, this strategy did not prove to provide significant survival benefit. Therefore, efforts to treat the tumor burden itself in addition to maintaining biliary patency became a focus of innovation and research in the endoscopic field. This study has led to the advent of therapies such as photodynamic therapy, radiofrequency ablation, and intraluminal brachytherapy. These options combined with biliary stenting have shown to not only offer the benefit of biliary decompression, but also to potentially improve stent patency and survival. Further, there is an anti-tumor effect of each of these modalities, portending an additional benefit in this subset of patients. Despite numerous retrospective and prospective studies assessing these ablative therapies, there is still a paucity of appropriately powered randomized controlled trials, and further research has yet to be done in the field. This review details the current literature entailing endobiliary ablative strategies.</p>","PeriodicalId":23267,"journal":{"name":"Translational gastroenterology and hepatology","volume":" ","pages":"63"},"PeriodicalIF":3.0,"publicationDate":"2021-10-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8573373/pdf/tgh-06-2020.02.03.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39644667","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 4
Acute pancreatitis in a patient with COVID-19: a case report. COVID-19患者急性胰腺炎1例报告
IF 3 4区 医学 Q1 Medicine Pub Date : 2021-10-25 eCollection Date: 2021-01-01 DOI: 10.21037/tgh-20-234
Chiranjeevi Gadiparthi, Sonmoon Mohapatra, Sowjanya Kanna, Vinit Vykuntam, William Chen

The global pandemic of coronavirus disease-2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is predominantly a respiratory illness, but gastrointestinal (GI) manifestations of variable severity have been reported. In patients with COVID-19 pneumonia, observational studies have demonstrated the elevation of pancreatic enzymes as surrogate markers for pancreatic injury without evidence of acute pancreatitis (AP). We report a case of AP in a patient with COVID-19 with SARS-CoV-2 as possible etiological agent with imaging evidence of pancreatitis. We hypothesize a causal relationship of SARS-CoV-2 in this patient with an otherwise unexplained presentation of AP after excluding the common causes. We postulate that AP in COVID-19 could be related to the abundant expression of angiotensin converting enzyme 2 (ACE 2) receptors in the pancreas which serve as viral entry binding receptors for SARS-CoV-2 or due to direct viral involvement of the pancreas. Although there seems to be an association between diabetes and AP, the available data regarding the etiological role of diabetes in causing AP is very limited. We also propose that imaging studies such as computerized tomography (CT) scan of the abdomen should be considered in the diagnosis of AP in patients with COVID-19 infection to exclude the false positive amylase and lipase.

由严重急性呼吸综合征冠状病毒2型(SARS-CoV-2)引起的冠状病毒病-2019 (COVID-19)全球大流行主要是一种呼吸道疾病,但也有不同严重程度的胃肠道(GI)表现的报道。在COVID-19肺炎患者中,观察性研究表明胰腺酶升高是胰腺损伤的替代标志物,没有急性胰腺炎(AP)的证据。我们报告一例AP在COVID-19患者中,SARS-CoV-2可能是病因,影像学证据为胰腺炎。在排除常见原因后,我们假设该患者的SARS-CoV-2与其他无法解释的AP表现存在因果关系。我们推测,COVID-19中的AP可能与胰腺中血管紧张素转换酶2 (ACE 2)受体的丰富表达有关,该受体作为SARS-CoV-2的病毒进入结合受体,或者与病毒直接累及胰腺有关。虽然糖尿病和AP之间似乎存在关联,但关于糖尿病在AP的病因学作用的现有数据非常有限。我们还建议在诊断COVID-19感染患者的AP时考虑影像学检查,如腹部CT扫描,以排除淀粉酶和脂肪酶的假阳性。
{"title":"Acute pancreatitis in a patient with COVID-19: a case report.","authors":"Chiranjeevi Gadiparthi,&nbsp;Sonmoon Mohapatra,&nbsp;Sowjanya Kanna,&nbsp;Vinit Vykuntam,&nbsp;William Chen","doi":"10.21037/tgh-20-234","DOIUrl":"https://doi.org/10.21037/tgh-20-234","url":null,"abstract":"<p><p>The global pandemic of coronavirus disease-2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is predominantly a respiratory illness, but gastrointestinal (GI) manifestations of variable severity have been reported. In patients with COVID-19 pneumonia, observational studies have demonstrated the elevation of pancreatic enzymes as surrogate markers for pancreatic injury without evidence of acute pancreatitis (AP). We report a case of AP in a patient with COVID-19 with SARS-CoV-2 as possible etiological agent with imaging evidence of pancreatitis. We hypothesize a causal relationship of SARS-CoV-2 in this patient with an otherwise unexplained presentation of AP after excluding the common causes. We postulate that AP in COVID-19 could be related to the abundant expression of angiotensin converting enzyme 2 (ACE 2) receptors in the pancreas which serve as viral entry binding receptors for SARS-CoV-2 or due to direct viral involvement of the pancreas. Although there seems to be an association between diabetes and AP, the available data regarding the etiological role of diabetes in causing AP is very limited. We also propose that imaging studies such as computerized tomography (CT) scan of the abdomen should be considered in the diagnosis of AP in patients with COVID-19 infection to exclude the false positive amylase and lipase.</p>","PeriodicalId":23267,"journal":{"name":"Translational gastroenterology and hepatology","volume":" ","pages":"65"},"PeriodicalIF":3.0,"publicationDate":"2021-10-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8573359/pdf/tgh-06-20-234.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39645101","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 5
Evaluating quality and completeness of gastrectomy for gastric cancer: review of surgical videos from the public domain. 评价胃癌胃切除术的质量和完整性:对公开领域手术视频的回顾。
IF 3 4区 医学 Q1 Medicine Pub Date : 2021-10-25 eCollection Date: 2021-01-01 DOI: 10.21037/tgh.2020.01.01
Matthew Dixon, Vanessa Palter, Savtaj Brar, Natalie Coburn

Background: YouTube® has provided a forum to share surgical videos in the public domain which may be used for education. The quality of surgery and accompanying educational material is unknown. YouTube® videos of gastrectomy with D2 lymphadenectomy (D2-LND) for gastric cancer were evaluated for quality and completeness.

Methods: YouTube® was searched using the terms "D2 lymphadenectomy" and "Gastric Cancer" for open and laparoscopic videos. The Korean Laparoscopic Gastrointestinal Surgical Society (KLASS) outlined 22 steps that define quality and completeness of D2-LND. These guidelines were used to score D2-LND for each video. Four physician reviewers independently scored each surgical video. Scores were compared using Student's t-test.

Results: Ten laparoscopic and 10 open surgery videos were assessed. Each video was scored for quality and completeness and assigned a score out of 22. Mean score for open D2-LND was 15 (95% CI: 12.54-17.46). Mean score for laparoscopic D2-LND was 15.4 (95% CI: 14.34-16.46; P=0.77). The most consistently performed steps were the dissection of lymph node stations 1, 3, 4 and 5. The most commonly omitted steps were the dissection of lymph node station 6: exposure and identification of the lowest anterior superior pancreaticoduodenal vein; removal of the prepancreatic soft tissues above the lowest anterior superior pancreaticoduodenal vein; removal of the prepancreatic soft tissues above the level of the bifurcation of the anterior superior pancreaticoduodenal vein and right gastroepiploic vein.

Conclusions: There is a wide range of quality and completeness of D2-LND videos. On average, D2-LND videos are only two-thirds complete.

背景:YouTube®提供了一个论坛,在公共领域分享手术视频,可用于教育。手术的质量和相关的教育材料是未知的。对胃癌胃切除术联合D2淋巴结切除术(D2- lnd)的YouTube®视频进行质量和完整性评估。方法:使用“D2淋巴结切除术”和“胃癌”搜索YouTube®,用于开放和腹腔镜视频。韩国腹腔镜胃肠外科学会(KLASS)概述了定义D2-LND质量和完整性的22个步骤。使用这些指南对每个视频进行D2-LND评分。四名医生独立对每个手术视频进行评分。分数比较采用学生t检验。结果:对10段腹腔镜手术视频和10段开放手术视频进行评价。每个视频的质量和完整性评分,并分配到22分。开放D2-LND的平均评分为15分(95% CI: 12.54-17.46)。腹腔镜下D2-LND的平均评分为15.4 (95% CI: 14.34-16.46;P = 0.77)。最一致执行的步骤是淋巴结站1、3、4和5的清扫。最常被忽略的步骤是淋巴结清扫第6站:暴露和识别胰十二指肠前上静脉最低位;胰前上静脉下方胰前软组织切除;胰前十二指肠前上静脉和右胃大网膜静脉分叉处以上的胰前软组织切除。结论:D2-LND影像的质量和完整性范围广。平均而言,2d - lnd视频只完成了三分之二。
{"title":"Evaluating quality and completeness of gastrectomy for gastric cancer: review of surgical videos from the public domain.","authors":"Matthew Dixon,&nbsp;Vanessa Palter,&nbsp;Savtaj Brar,&nbsp;Natalie Coburn","doi":"10.21037/tgh.2020.01.01","DOIUrl":"https://doi.org/10.21037/tgh.2020.01.01","url":null,"abstract":"<p><strong>Background: </strong>YouTube<sup>®</sup> has provided a forum to share surgical videos in the public domain which may be used for education. The quality of surgery and accompanying educational material is unknown. YouTube<sup>®</sup> videos of gastrectomy with D2 lymphadenectomy (D2-LND) for gastric cancer were evaluated for quality and completeness.</p><p><strong>Methods: </strong>YouTube<sup>®</sup> was searched using the terms \"D2 lymphadenectomy\" and \"Gastric Cancer\" for open and laparoscopic videos. The Korean Laparoscopic Gastrointestinal Surgical Society (KLASS) outlined 22 steps that define quality and completeness of D2-LND. These guidelines were used to score D2-LND for each video. Four physician reviewers independently scored each surgical video. Scores were compared using Student's <i>t</i>-test.</p><p><strong>Results: </strong>Ten laparoscopic and 10 open surgery videos were assessed. Each video was scored for quality and completeness and assigned a score out of 22. Mean score for open D2-LND was 15 (95% CI: 12.54-17.46). Mean score for laparoscopic D2-LND was 15.4 (95% CI: 14.34-16.46; P=0.77). The most consistently performed steps were the dissection of lymph node stations 1, 3, 4 and 5. The most commonly omitted steps were the dissection of lymph node station 6: exposure and identification of the lowest anterior superior pancreaticoduodenal vein; removal of the prepancreatic soft tissues above the lowest anterior superior pancreaticoduodenal vein; removal of the prepancreatic soft tissues above the level of the bifurcation of the anterior superior pancreaticoduodenal vein and right gastroepiploic vein.</p><p><strong>Conclusions: </strong>There is a wide range of quality and completeness of D2-LND videos. On average, D2-LND videos are only two-thirds complete.</p>","PeriodicalId":23267,"journal":{"name":"Translational gastroenterology and hepatology","volume":" ","pages":"57"},"PeriodicalIF":3.0,"publicationDate":"2021-10-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8573372/pdf/tgh-06-2020.01.01.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39644661","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 3
Enhancing polyp detection: technological advances in colonoscopy imaging. 增强息肉检测:结肠镜成像的技术进展。
IF 3 4区 医学 Q1 Medicine Pub Date : 2021-10-25 eCollection Date: 2021-01-01 DOI: 10.21037/tgh.2020.02.05
Antonio Lee, Nicholas Tutticci

The detection and removal of polyps at colonoscopy is core to the current colorectal cancer (CRC) prevention strategy. However, colonoscopy is flawed with a well described miss rate and variability in detection rates associated with incomplete protection from CRC. Consequently, there is significant interest in techniques and technologies which increase polyp detection with the aim to remedy colonoscopy's ills. Technologic advances in colonoscope imaging are numerous and include; increased definition of imaging, widening field of view, virtual technologies to supplant conventional chromocolonoscopy (CC) and now computer assisted detection. However, despite nearly two decades of technologic advances, data on gains in detection from individual technologies have been modest at best and heterogenous and conflicted as a rule. This state of detection technology science is exacerbated by use of relatively blunt metrics of improvement without consensus, the myopic search for gains over single generations of technology improvement and an unhealthy focus on adenomatous lesions. Yet there remains cause for optimism as detection gains from new technology, while small, may still improve CRC prevention. The technologies are also readily available in current generation colonoscopes and have roles beyond simply detection such as lesion characterization, further improving their worth. Coupled with the imminent expansion of computer assisted detection the detection future from colonoscope imaging advances looks bright. This review aims to cover the major imaging advances and evidence for improvement in polyp detection.

结肠镜下息肉的发现和切除是当前结直肠癌预防策略的核心。然而,结肠镜检查是有缺陷的,漏检率和检出率的变异性与CRC的不完全保护有关。因此,有显著的兴趣技术和技术,以增加息肉的检测,目的是补救结肠镜的疾病。结肠镜成像的技术进步很多,包括;提高成像清晰度,扩大视野,虚拟技术取代传统的彩色结肠镜检查(CC)和现在的计算机辅助检测。然而,尽管技术取得了近二十年的进步,但个别技术在检测方面取得的进展的数据充其量是有限的,而且通常是不同的和相互矛盾的。检测技术科学的这种状态由于使用相对钝钝的没有共识的改进指标、对单代技术改进的短视追求以及对腺瘤病变的不健康关注而加剧。然而,我们仍然有理由乐观,因为新技术的检测收益虽然很小,但仍可能改善结直肠癌的预防。这些技术在当代结肠镜中也很容易获得,并且除了简单地检测病变特征外,还具有其他作用,进一步提高了它们的价值。再加上计算机辅助检测的即将扩展,结肠镜成像的检测前景看起来很光明。这篇综述旨在涵盖主要的影像学进展和证据,以改善息肉的检测。
{"title":"Enhancing polyp detection: technological advances in colonoscopy imaging.","authors":"Antonio Lee,&nbsp;Nicholas Tutticci","doi":"10.21037/tgh.2020.02.05","DOIUrl":"https://doi.org/10.21037/tgh.2020.02.05","url":null,"abstract":"<p><p>The detection and removal of polyps at colonoscopy is core to the current colorectal cancer (CRC) prevention strategy. However, colonoscopy is flawed with a well described miss rate and variability in detection rates associated with incomplete protection from CRC. Consequently, there is significant interest in techniques and technologies which increase polyp detection with the aim to remedy colonoscopy's ills. Technologic advances in colonoscope imaging are numerous and include; increased definition of imaging, widening field of view, virtual technologies to supplant conventional chromocolonoscopy (CC) and now computer assisted detection. However, despite nearly two decades of technologic advances, data on gains in detection from individual technologies have been modest at best and heterogenous and conflicted as a rule. This state of detection technology science is exacerbated by use of relatively blunt metrics of improvement without consensus, the myopic search for gains over single generations of technology improvement and an unhealthy focus on adenomatous lesions. Yet there remains cause for optimism as detection gains from new technology, while small, may still improve CRC prevention. The technologies are also readily available in current generation colonoscopes and have roles beyond simply detection such as lesion characterization, further improving their worth. Coupled with the imminent expansion of computer assisted detection the detection future from colonoscope imaging advances looks bright. This review aims to cover the major imaging advances and evidence for improvement in polyp detection.</p>","PeriodicalId":23267,"journal":{"name":"Translational gastroenterology and hepatology","volume":" ","pages":"61"},"PeriodicalIF":3.0,"publicationDate":"2021-10-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8573375/pdf/tgh-06-2020.02.05.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39644665","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 2
Minimally invasive surgery of the pancreas: a narrative review of current practice. 胰腺微创手术:当前实践的叙述回顾。
IF 3 4区 医学 Q1 Medicine Pub Date : 2021-07-25 eCollection Date: 2021-01-01 DOI: 10.21037/tgh-20-220
Morgan K Richards, Matthew S Clifton

Minimally invasive surgery has moved from the fringe of pediatric surgery to the mainstream to address a variety of problems. Pancreatic pathology, though uncommon and complex, is frequently amenable to laparoscopic intervention. Indications for pediatric pancreatic operative intervention includes trauma, congenital hyperinsulinemia and neoplasm. Children may require distal pancreatectomy, subtotal pancreatectomy, enucleation, lateral pancreaticojejunostomy and pancreaticoduodenectomy. Of these operations, all but pancreaticoduodenectomy have been successfully described in children using a minimally invasive approach. Traumatic transection of the main pancreatic duct may require operative intervention if endoscopic techniques are unsuccessful. Distal pancreatectomy has been successfully utilized in this circumstance. Additionally, near total pancreatectomy may also be performed laparoscopically although successful reports are limited. Enucleation, especially with the use of intraoperative ultrasound may avoid a large laparotomy for isolated benign masses. Finally, chronic pancreatitis resulting in a dilated main pancreatic duct may benefit from a lateral pancreaticojejunostomy. This operation has also successfully been performed in children. Included is a review of pediatric pancreatic minimally invasive operations paired with corresponding pathology.

微创手术已经从儿科外科的边缘发展成为解决各种问题的主流。胰腺病理,虽然罕见和复杂,是经常适用于腹腔镜干预。小儿胰腺手术干预的适应症包括创伤、先天性高胰岛素血症和肿瘤。儿童可能需要远端胰切除术、次全胰切除术、去核术、外侧胰空肠吻合术和胰十二指肠切除术。在这些手术中,除胰十二指肠切除术外,所有手术均采用微创方法成功地在儿童中进行。如果内窥镜技术不成功,主胰管的外伤性横断可能需要手术干预。远端胰腺切除术已成功应用于这种情况。此外,近全胰切除术也可以在腹腔镜下进行,尽管成功的报道有限。摘除核,特别是术中超声的使用,可以避免对孤立的良性肿块进行大的剖腹手术。最后,慢性胰腺炎导致主胰管扩张可能受益于外侧胰空肠吻合术。该手术在儿童中也已成功实施。包括小儿胰腺微创手术与相应病理配对的回顾。
{"title":"Minimally invasive surgery of the pancreas: a narrative review of current practice.","authors":"Morgan K Richards,&nbsp;Matthew S Clifton","doi":"10.21037/tgh-20-220","DOIUrl":"https://doi.org/10.21037/tgh-20-220","url":null,"abstract":"<p><p>Minimally invasive surgery has moved from the fringe of pediatric surgery to the mainstream to address a variety of problems. Pancreatic pathology, though uncommon and complex, is frequently amenable to laparoscopic intervention. Indications for pediatric pancreatic operative intervention includes trauma, congenital hyperinsulinemia and neoplasm. Children may require distal pancreatectomy, subtotal pancreatectomy, enucleation, lateral pancreaticojejunostomy and pancreaticoduodenectomy. Of these operations, all but pancreaticoduodenectomy have been successfully described in children using a minimally invasive approach. Traumatic transection of the main pancreatic duct may require operative intervention if endoscopic techniques are unsuccessful. Distal pancreatectomy has been successfully utilized in this circumstance. Additionally, near total pancreatectomy may also be performed laparoscopically although successful reports are limited. Enucleation, especially with the use of intraoperative ultrasound may avoid a large laparotomy for isolated benign masses. Finally, chronic pancreatitis resulting in a dilated main pancreatic duct may benefit from a lateral pancreaticojejunostomy. This operation has also successfully been performed in children. Included is a review of pediatric pancreatic minimally invasive operations paired with corresponding pathology.</p>","PeriodicalId":23267,"journal":{"name":"Translational gastroenterology and hepatology","volume":" ","pages":"38"},"PeriodicalIF":3.0,"publicationDate":"2021-07-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8343413/pdf/tgh-06-20-220.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39335347","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 2
Pediatric surgical care: have we done enough? 小儿外科护理:我们做得够不够?
IF 3 4区 医学 Q1 Medicine Pub Date : 2021-07-25 eCollection Date: 2021-01-01 DOI: 10.21037/tgh-2021-01
Eduardo A Perez, Samir Pandya, Matthew S Clifton
{"title":"Pediatric surgical care: have we done enough?","authors":"Eduardo A Perez,&nbsp;Samir Pandya,&nbsp;Matthew S Clifton","doi":"10.21037/tgh-2021-01","DOIUrl":"https://doi.org/10.21037/tgh-2021-01","url":null,"abstract":"","PeriodicalId":23267,"journal":{"name":"Translational gastroenterology and hepatology","volume":" ","pages":"30"},"PeriodicalIF":3.0,"publicationDate":"2021-07-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8343513/pdf/tgh-06-2021-01.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39335401","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Translational gastroenterology and hepatology
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1